Novartis FY2027 EPS Estimate Raised by Zacks Research

Novartis AG (NYSE:NVS) – Equities researchers at Zacks Research lifted their FY2027 earnings per share (EPS) estimates for shares of Novartis in a research report issued to clients and investors on Thursday, September 4th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $10.13 for the year, up from their prior forecast of $10.08. The consensus estimate for Novartis’ current full-year earnings is $8.45 per share.

Other equities research analysts also recently issued reports about the company. Wall Street Zen downgraded Novartis from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 22nd. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Novartis in a research note on Thursday, August 21st. Finally, Morgan Stanley raised Novartis from an “underweight” rating to an “equal weight” rating and set a $123.00 price objective on the stock in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Novartis currently has a consensus rating of “Hold” and an average target price of $124.33.

Novartis Stock Up 1.0%

NVS opened at $129.76 on Friday. Novartis has a fifty-two week low of $96.06 and a fifty-two week high of $130.46. The business has a 50-day moving average of $121.25 and a 200-day moving average of $115.10. The company has a debt-to-equity ratio of 0.53, a current ratio of 0.82 and a quick ratio of 0.62. The company has a market capitalization of $274.10 billion, a PE ratio of 18.89, a price-to-earnings-growth ratio of 1.80 and a beta of 0.63.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Thursday, July 17th. The company reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Novartis had a return on equity of 41.08% and a net margin of 25.64%.The company had revenue of $14.05 billion during the quarter, compared to the consensus estimate of $13.94 billion. During the same period last year, the business earned $1.97 EPS. The business’s quarterly revenue was up 12.3% on a year-over-year basis.

Institutional Trading of Novartis

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Raiffeisen Bank International AG acquired a new stake in Novartis in the 4th quarter valued at approximately $25,000. Nexus Investment Management ULC acquired a new stake in Novartis in the 1st quarter valued at approximately $25,000. WPG Advisers LLC acquired a new stake in Novartis in the 1st quarter valued at approximately $25,000. Tsfg LLC grew its holdings in Novartis by 366.0% in the 1st quarter. Tsfg LLC now owns 233 shares of the company’s stock valued at $26,000 after buying an additional 183 shares during the last quarter. Finally, GFG Capital LLC acquired a new stake in Novartis in the 2nd quarter valued at approximately $26,000. Institutional investors and hedge funds own 13.12% of the company’s stock.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.